Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

Kyle Blankenship

Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Apellis scored a breakthrough win earlier this summer for its own complement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

Kyle Blankenship

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

After stock slides, Amgen addresses bone density talk on obesity drug

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Apel­lis turns up mixed re­sults in close­ly watched eye dis­ease tests. Are the da­ta strong enough for ap­proval?

Kyle Blankenship

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Apellis turns up mixed results in closely watched eye disease tests. Are the data strong enough for approval?

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

After stock slides, Amgen addresses bone density talk on obesity drug

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?